Results 121 to 130 of about 198,351 (337)

Post‐Viral Acquired Idiopathic Purpura Fulminans Caused by Anti‐Protein S Antibodies

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Acquired Idiopathic purpura fulminans is a rare pathology caused by anti‐protein S antibodies. We have conducted a literature review focusing on the most recent developments in diagnosis and management. Diagnosis is based on the demonstration of typical necrotic purpura lesions on the legs. Treatment must be initiated without delay by infusion
Alexandre Theron   +2 more
wiley   +1 more source

ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

open access: yesAnnual Review of Medicine, 2015
Pathogenesis of thrombotic thrombocytopenic purpura (TTP) was a mystery for over half a century until the discovery of ADAMTS13. ADAMTS13 is primarily synthesized in the liver, and its main function is to cleave von Willebrand factor (VWF) anchored on ...
X. Zheng
semanticscholar   +1 more source

Cutaneous periumbilical purpura in disseminated strongyloidiasis in cancer patients: a pathognomonic feature of potentially lethal disease?

open access: yesBrazilian Journal of Infectious Diseases
Cutaneous manifestations in disseminated strongyloidiasis are infrequent but should raise the suspicion for its diagnosis. We retrospectively evaluated the charts of six patients with cancer and a proven diagnosis of disseminated strongyloidiasis.
Jorge I. F. Salluh   +5 more
doaj   +1 more source

Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.

open access: yesBlood, 2016
Publisher's Note: There is an [Inside Blood Commentary][1] on this article in this issue. To the editor: Recent systematic reviews assessing the role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura (TTP)[1 ...
E. E. Page   +4 more
semanticscholar   +1 more source

PURPURA FULMINANS. [PDF]

open access: yesThe Lancet, 1912
n ...
openaire   +2 more sources

Predictors of response to emergent therapies in paediatric immune thrombocytopenia

open access: yesBritish Journal of Haematology, EarlyView.
Emergent therapies (ET), which include intravenous immunoglobulin (IVIG), corticosteroids and intravenous anti‐Rho(D) immunoglobulin, are used to treat acute episodes of bleeding in children with immune thrombocytopenia (ITP). Through comparison of clinical characteristics in paediatric patients with ITP responsive to ET versus those non‐responsive to ...
Candelaria O'Farrell   +7 more
wiley   +1 more source

Bilateral Nicolau Syndrome Following Intramuscular Gentamicin Injections

open access: yes
JEADV Clinical Practice, EarlyView.
Konstantina Kotsia   +3 more
wiley   +1 more source

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF‐McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the diagnosis and management of VWD all utilised GRADE methodology.
Mark W. Skinner   +59 more
wiley   +1 more source

Çocuklarda Henoch Schönlein purpurası: 46 olgunun geriye dönük analizi ve literatürün incelenmesi

open access: yesSakarya Tıp Dergisi, 2015
AmaçHenoch Schönlein purpurası (HSP) tanılı hastaların klinik ve laboratuvar karakteristiklerinin değerlendirilmesi, prognozu etkileyen risk faktörlerinin literatür eşliğinde incelenmesi.Gereç ve yöntemAbant İzzet Baysal Üniversitesi Tıp Fakültesi Çocuk ...
Betül Şereflican   +4 more
doaj   +1 more source

Bad-Looking, Good-Natured Disease: Acute Hemorrhagic Edema of Infancy

open access: yesGüncel Pediatri, 2017
Acute hemorrhagic edema of infancy is a skin limited leukocytoclastic vasculitis occurring in children younger than 2 years old. Although it has an alarming start, it has a good prognosis.
Esra Ülgen Temel   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy